证券日报网讯2月3日，赛分科技在互动平台回答投资者提问时表示，公司是全球范围内少数同时具备分 析色谱及工业纯化的先进研发及规模化生产能力的企业之一，是国内竞争中的主要参与者。公司依托自 主可控的工艺平台、行业领先的技术实力与卓越的产品表现，与国内生物医药行业各细分领域的领军企 业建立了色谱填料长期合作关系。未来，伴随下游医药行业市场规模持续扩容、国产替代进程加速推 进，叠加公司海外业务的稳步拓展，公司的市场占有率将进一步提升。 ...

Group 1 - The core viewpoint of the news is that Suzhou Saifen Technology Co., Ltd. has commenced construction on a new project aimed at increasing its production capacity for chromatography media, which is essential for biopharmaceutical separation and purification [1][2] - The new project in Yangzhou will add an annual production capacity of 200,000 liters of chromatography media, including affinity chromatography fillers, ion exchange fillers, and composite chromatography fillers, with a total construction area of approximately 21,000 square meters [1] - Saifen Technology has established itself as a leading domestic chromatography filler enterprise, actively participating in the rapid development of China's biopharmaceutical industry and the localization of the supply chain, with over 100 clinical and commercial projects in various biopharmaceutical segments [1][2] Group 2 - Since its listing, Saifen Technology has shown strong business growth, achieving operating revenue of 302 million yuan in the first three quarters of 2025, a year-on-year increase of 38.39%, and a net profit attributable to shareholders of 93.21 million yuan, up 71.07% [2] - The Yangzhou Phase II project is a key strategic move for the company to solidify its core business and expand production capacity, marking a significant step in leveraging capital markets to accelerate its strategic development [2] - The new project is expected to enhance the company's service capabilities to partners, improve delivery efficiency, and support stable production and capacity expansion for collaborative projects, while also aiding in the company's overseas market expansion strategy [2]

Core Viewpoint - The company, Saifen Technology, is expected to achieve significant revenue and profit growth in the first half of 2025, driven by its focus on analytical chromatography and industrial purification sectors, alongside strong market demand and strategic partnerships [1][2]. Company Performance - The company forecasts revenue between 180 million to 186 million yuan, representing a year-on-year growth of 18% to 22% [1]. - Expected net profit attributable to shareholders is projected to be between 51 million to 55 million yuan, indicating a year-on-year increase of 34% to 44% [1]. - The net profit after deducting non-recurring gains and losses is anticipated to be between 45 million to 47 million yuan, reflecting a year-on-year growth of 18% to 23% [1]. Market Position and Strategy - Saifen Technology holds three core technologies: microspheres, surface modification, and functional group ligands, and has established strategic partnerships with leading companies in the antibody, insulin, GLP-1, and recombinant protein sectors [1]. - The company is actively developing purification solutions for oligonucleotides, collagen, and blood products, enhancing its competitive edge across various segments of the biopharmaceutical market [1]. Industry Trends - The Chinese biopharmaceutical chromatography medium market is projected to reach between 6 billion to 9 billion yuan, accounting for approximately 15% to 20% of the global market [2]. - There is a strong trend towards domestic substitution in the industry, with leading domestic companies gaining market advantages through technological depth, scale production capabilities, and quality systems [2]. - The company is expanding its core product capacity and shortening delivery times to meet the rapidly growing market demand, with a significant capacity expansion project underway at its Yangzhou factory [2].

Macro Overview - The Federal Reserve is expected to maintain interest rates for a longer period, with a higher probability of rate cuts occurring in the second half of the year, although the likelihood of a July cut is decreasing due to slow tariff negotiations and resilient economic growth [1][2][7] - The A-share market is anticipated to show stronger resilience due to ongoing policy support aimed at stabilizing and activating the capital market, with a focus on mergers and acquisitions for company transformation [1][12] Equity Market Insights - The U.S. stock market is facing multiple pressures that could trigger a downward spiral, despite some recovery due to eased tariff policies and fiscal stimulus expectations [1][17] - The A-share market is expected to benefit from policies promoting long-term capital inflows and corporate restructuring, with a focus on high-margin assets and sectors boosted by policy support [1][17] Fixed Income Strategy - The convertible bond market is experiencing a decline, with a focus on identifying undervalued securities and opportunities related to redemption clauses [19][20] - The performance of convertible bonds is closely tied to the overall equity market, with a recommendation for a diversified portfolio including specific convertible bonds [19][21] Non-Banking Financial Sector - The "Action Plan for Promoting the High-Quality Development of Public Funds" aims to enhance investor returns and expand the scale of equity investments in public funds, which is crucial for long-term capital market stability [24][28] - The plan emphasizes performance-based fee structures and long-term investment strategies to improve the overall quality of the public fund industry [25][26] Automotive Industry - The automotive sector has shown strong performance in Q1 2025, with significant fund allocation and a continuous increase in holdings by public funds, driven by favorable policies and market conditions [30][31] - The sector is expected to maintain high growth momentum due to new product launches and consumer demand stimulation [30][31] Pharmaceutical Sector - The pharmaceutical industry is under pressure due to cost control measures, with a notable decline in revenue and profit margins, but there are signs of recovery in the innovative drug segment [36][39] - The innovative drug sector is projected to benefit from supportive policies and improving market conditions, leading to potential value recovery [38][39]

Group 1 - The company reported a revenue of 782 million yuan for 2024, representing a year-on-year growth of 33.33%, with a net profit attributable to the parent company of 83 million yuan, up 20.82% year-on-year [1] - In Q1 2025, the company achieved a revenue of 189 million yuan, a year-on-year increase of 22.39%, and a net profit attributable to the parent company of 29 million yuan, up 72.98% year-on-year [1] - The core business of chromatography fillers and media generated a revenue of 451 million yuan in 2024, with a year-on-year growth of 10.20% [2] Group 2 - The newly added chromatography analysis instruments and accessories contributed a revenue of 154 million yuan, primarily from the consolidation of the acquired company Fuli Instruments [2] - The market for chromatography fillers is expanding, with a current domestic market penetration rate of only about 10%, indicating significant potential for domestic substitution [3] - The company has established strategic cooperation agreements with five major clients, resulting in a sales volume of 224 million yuan, accounting for 50% of the revenue from chromatography fillers [3] Group 3 - The company is evolving into a leading domestic supplier of chromatography fillers, consumables, and instruments, driven by underlying technology [4] - Revenue projections for 2025-2027 are 977 million yuan, 1.17 billion yuan, and 1.37 billion yuan, with net profits of 134 million yuan, 203 million yuan, and 290 million yuan respectively [4] - The current stock price corresponds to a PE ratio of 67, 45, and 31 times for 2025-2027 [4]